{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:52:01Z","timestamp":1786326721963,"version":"build-2736575974"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to the cancer itself or the cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. We summarize the most common acute CV complications of cytotoxic, targeted, and immune-based therapies. This is followed by a proposal for a multidisciplinary approach where acute cardiologists work close together with the treating oncologists, haematologists, and radiation specialists, especially in situations where immediate therapeutic decisions are needed. In this first part, we further focus on the management of acute coronary syndromes and acute pericardial diseases in patients with cancer.<\/jats:p>","DOI":"10.1093\/ehjacc\/zuab056","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T11:56:59Z","timestamp":1625054219000},"page":"947-959","source":"Crossref","is-referenced-by-count":51,"title":["Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology\u2014Part 1: acute coronary syndromes and acute pericardial diseases"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-3003","authenticated-orcid":false,"given":"Sofie A","family":"Gevaert","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ghent University Hospital , C Heymanslaan 10, 9000 Gent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and University of Oslo , Kirkeveien 166, 0450 Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Sinnaeve","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Leuven , Herestraat 49, 3000 Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sambola","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Vall d\u2019Hebron, Universitat Auton\u00f2ma, CIBER-CV , Passeig de la Vall d'Hebron 119, 08035 Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and University of Oslo , Kirkeveien 166, 0450 Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0804-8194","authenticated-orcid":false,"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge Hospital, GIGA Cardiovascular Science and Department of Cardiology, CHU Sart Tilman , Avenue del'H\u00f4pital 1, 4000 Li\u00e8ge,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen University Medical Center Groningen and University of Groningen , Hanzeplein 1, 9713 GZ Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College , Sydney street, SW3 6NP London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"University of Cyprus Medical School , Agio Nikolaou street 93, 2408 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Lee","sequence":"additional","affiliation":[{"name":"Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King\u2019s College , Strand, WC2R 2LS London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia and Policlinico Di Modena , Via Giuseppe Campi 287, 41125 Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London\/University College London Hospitals , Huntley street 72, WC1E 6DD London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Okines","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Royal Marsden NHS Foundation Trust , Fulham road 203, SW3 6JJ London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-7228","authenticated-orcid":false,"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[{"name":"Insubria University , Via Ravasi 2, 21100 Varese,","place":["Italy"]},{"name":"LARC (Laboratorio Analisi e Ricerca Clinica) , Via Mombarcaro 80, 10136 Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"2026080909214183300_zuab056-B1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"2026080909214183300_zuab056-B2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026080909214183300_zuab056-B4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080909214183300_zuab056-B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026080909214183300_zuab056-B6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909214183300_zuab056-B7","first-page":"993","article-title":"Organization of intensive cardiac care units in Europe: results of a multinational survey","volume":"9","author":"Claeys","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080909214183300_zuab056-B8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/106002809402800314","article-title":"Fluorouracil cardiotoxicity","volume":"28","author":"Anand","year":"1994","journal-title":"Ann Pharmacother"},{"key":"2026080909214183300_zuab056-B11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-associated cardiac disease: a practical approach to diagnosis and management","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909214183300_zuab056-B12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909214183300_zuab056-B13","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"Demers","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080909214183300_zuab056-B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.14503\/THIJ-14-4619","article-title":"Coronary embolization from a left atrial myxoma containing malignant lymphoma cells","volume":"42","author":"Pineda","year":"2015","journal-title":"Tex Heart Inst J"},{"key":"2026080909214183300_zuab056-B15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0936-6555(05)80328-0","article-title":"Non-Hodgkin's lymphoma: an unusual cause of myocardial infarction and hypercalcaemia","volume":"5","author":"Harris","year":"1993","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026080909214183300_zuab056-B16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/eurheartj\/ehaa909","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin Cardiol"},{"key":"2026080909214183300_zuab056-B18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11936-017-0535-5","article-title":"Ischemic heart disease: special considerations in cardio-oncology","volume":"19","author":"Giza","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026080909214183300_zuab056-B19","article-title":"Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis","author":"Mohamed","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080909214183300_zuab056-B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026080909214183300_zuab056-B21","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.amjcard.2013.08.019","article-title":"Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention","volume":"112","author":"Velders","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026080909214183300_zuab056-B24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080909214183300_zuab056-B25","first-page":"E202","article-title":"SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia intervencionista","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080909214183300_zuab056-B26","first-page":"631","article-title":"Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy","volume":"7","author":"Iannaccone","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080909214183300_zuab056-B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B28","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes","volume":"109","author":"Sarkiss","year":"2007","journal-title":"Cancer"},{"key":"2026080909214183300_zuab056-B30","doi-asserted-by":"crossref","first-page":"S4367","DOI":"10.21037\/jtd.2018.12.79","article-title":"Arterial events in cancer patients-the case of acute coronary thrombosis","volume":"10","author":"Oren","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026080909214183300_zuab056-B31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40256-018-0286-z","article-title":"Acute coronary syndrome in cancer patients","volume":"18","author":"Yetis Sayin","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080909214183300_zuab056-B32","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jcin.2017.06.068","article-title":"Re-evaluating the safety of drug-eluting stents in cancer patients","volume":"10","author":"Ganatra","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909214183300_zuab056-B33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909214183300_zuab056-B34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080909214183300_zuab056-B35","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133(Suppl 2","author":"Liebman","year":"2014","journal-title":"Thromb Res"},{"key":"2026080909214183300_zuab056-B36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B37","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"2026080909214183300_zuab056-B38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","article-title":"Capecitabine-induced chest pain relieved by diltiazem","volume":"110","author":"Ambrosy","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002800050877","article-title":"Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report","volume":"43","author":"Akpek","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026080909214183300_zuab056-B40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"2026080909214183300_zuab056-B41","first-page":"487","article-title":"Cardiotoxicity of sequential aromatase inhibitors use in women with breast cancer","volume":"28","author":"Khosrow-Khavar","year":"2020","journal-title":"Am J Epidemiol"},{"key":"2026080909214183300_zuab056-B42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"key":"2026080909214183300_zuab056-B43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000348559","article-title":"Malignant pericardial effusion","volume":"124","author":"Burazor","year":"2013","journal-title":"Cardiology"},{"key":"2026080909214183300_zuab056-B44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2015.11.023","article-title":"Cause and long-term outcome of cardiac tamponade","volume":"117","author":"S\u00e1nchez-Enrique","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/clc.22295","article-title":"Primary malignancies of the heart and pericardium","volume":"37","author":"Burazor","year":"2014","journal-title":"Clin Cardiol"},{"key":"2026080909214183300_zuab056-B46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11886-016-0776-z","article-title":"Echocardiographic assessment of cardiotoxic effects of cancer therapy","volume":"18","author":"Bottinor","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2026080909214183300_zuab056-B47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijrobp.2017.05.022","article-title":"Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"99","author":"Ning","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909214183300_zuab056-B48","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909214183300_zuab056-B49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jrr\/rry029","article-title":"Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique","volume":"59","author":"Takata","year":"2018","journal-title":"J Radiat Res"},{"key":"2026080909214183300_zuab056-B50","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080909214183300_zuab056-B51","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","article-title":"Cardiovascular magnetic resonance in the oncology patient","volume":"11","author":"Jordan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909214183300_zuab056-B52","doi-asserted-by":"crossref","first-page":"e007598","DOI":"10.1161\/JAHA.117.007598","article-title":"Etiology and long-term outcome of patients undergoing pericardiocentesis","volume":"6","author":"Strobbe","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026080909214183300_zuab056-B53","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.amjcard.2013.05.066","article-title":"Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy","volume":"112","author":"Patel","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.25283","article-title":"Predictors of hospital discharge in cancer patients with pericardial effusion undergoing surgical pericardial drainage","volume":"119","author":"Kazantzis","year":"2019","journal-title":"J Surg Oncol"},{"key":"2026080909214183300_zuab056-B55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tcm.2018.10.016","article-title":"A contemporary look at pericardiocentesis","volume":"29","author":"Sinnaeve","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"2026080909214183300_zuab056-B56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00059-019-4833-4","article-title":"Management of neoplastic pericardial disease","volume":"45","author":"Zhang","year":"2020","journal-title":"Herz"},{"key":"2026080909214183300_zuab056-B57","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.carrev.2017.03.029","article-title":"Percutaneous balloon pericardiotomy: treatment of choice in patients with advanced oncological disease and severe pericardial effusion","volume":"18","author":"Irazusta","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"2026080909214183300_zuab056-B58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3747\/co.22.2698","article-title":"Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison","volume":"22","author":"Labbe","year":"2015","journal-title":"Curr Oncol"},{"key":"2026080909214183300_zuab056-B59","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors","volume":"123","author":"Palaskas","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026080909214183300_zuab056-B60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080909214183300_zuab056-B61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncy.21790","article-title":"Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens","volume":"125","author":"Saab","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2026080909214183300_zuab056-B62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart"},{"key":"2026080909214183300_zuab056-B63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ajcp\/aqv021","article-title":"A minimum volume of more than 60 ml is necessary for adequate cytologic diagnosis of malignant pericardial effusions","volume":"145","author":"Rooper","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"2026080909214183300_zuab056-B64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-012-9327-x","article-title":"Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion","volume":"18","author":"Karatolios","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026080909214183300_zuab056-B65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ehjci\/jev225","article-title":"The role of early contrast-enhanced chest computed tomography in the aetiological diagnosis of patients presenting with cardiac tamponade or large pericardial effusion","volume":"17","author":"Maggiolini","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909214183300_zuab056-B66","first-page":"1","article-title":"Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation","author":"Defruyt","year":"2020","journal-title":"Acta Clin Belg"},{"key":"2026080909214183300_zuab056-B67","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/heartjnl-2015-307907","article-title":"Systematic review of percutaneous interventions for malignant pericardial effusion","volume":"101","author":"Virk","year":"2015","journal-title":"Heart"},{"key":"2026080909214183300_zuab056-B68","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.1996.14.12.3141","article-title":"Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade","volume":"14","author":"Liu","year":"1996","journal-title":"J Clin Oncol"},{"key":"2026080909214183300_zuab056-B69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.lungcan.2010.10.013","article-title":"Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study","volume":"72","author":"Lestuzzi","year":"2011","journal-title":"Lung Cancer"},{"key":"2026080909214183300_zuab056-B70","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"key":"2026080909214183300_zuab056-B71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"2026080909214183300_zuab056-B72","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/CIRCULATIONAHA.116.024041","article-title":"Pericarditis as a marker of occult cancer and a prognostic factor for cancer mortality","volume":"136","author":"Sogaard","year":"2017","journal-title":"Circulation"},{"key":"2026080909214183300_zuab056-B73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2015.04.265","article-title":"Value of pericardial effusion as imaging biomarker in acute pericarditis, do we need to focus on more appropriate ones?","volume":"191","author":"Bogaert","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026080909214183300_zuab056-B74","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909214183300_zuab056-B75","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080909214183300_zuab056-B76","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11886-019-1225-6","article-title":"Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management","volume":"21","author":"Ala","year":"2019","journal-title":"Curr Cardiol Rep"}],"container-title":["European Heart Journal Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/8\/947\/60907969\/zuab056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/8\/947\/60907969\/zuab056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:21:58Z","timestamp":1786281718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/10\/8\/947\/6359200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":76,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,28]]},"published-print":{"date-parts":[[2021,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuab056","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,8,28]]}}}